Anti-ADAM9/Pamirtecan Antibody-drug Conjugate DB-1317

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) a disintegrin and metalloproteinase domain 9 (ADAM9) conjugated to the cytotoxic DNA topoisomerase I inhibitor pamirtecan, with potential antineoplastic activity. Upon administration of anti-ADAM9 ADC DB-1317, the anti-ADAM9 monoclonal antibody moiety targets and binds to ADAM9 on tumor cells. Upon binding, internalization, and linker cleavage, pamirtecan is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. In addition, DB-1317 induces a bystander effect on neighboring cells in the tumor environment and induces antibody-dependent cell-mediated cytotoxicity (ADCC). This further inhibits the proliferation of tumor cells. ADAM9, belonging to the ADAM family of proteases, plays a key role in cytokine and growth factor shedding and cell migration. It is overexpressed on multiple solid tumors while minimally expressed on normal tissue. Dysregulation of ADAM9 plays a key role in suppressive tumor microenvironment, tumor progression, migration and metastasis. Its expression is correlated with poor prognosis.

**Synonyms:** - ADC DB-1317 - Anti-ADAM9 ADC DB-1317 - Anti-ADAM9 Antibody-drug Conjugate DB-1317 - Anti-ADAM9/P1003 Antibody-drug Conjugate DB-1317 - Antibody-drug Conjugate DB-1317 - DB 1317 - DB-1317 - DB1317